DIABETES CIES SEARCH ENGINE [SELECTED WEBSITES]

Showing posts with label Eisai. Show all posts
Showing posts with label Eisai. Show all posts

Monday, January 23, 2012

Eisai and EIDIA : Launch of LIFE CHECK, a Self-monitoring Blood Glucose Meter That is Easy for Elderly Diabetes Patients to Use

Eisai
January 19, 2012 - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) and its diagnostics subsidiary EIDIA Co., Ltd. (Headquarters: Tokyo, President & CEO: Keisuke Watanabe, “EIDIA”) announced that EIDIA will launch LIFE CHECK, a self-monitoring blood glucose meter manufactured by Gunze Limited (Headquarters: Osaka, President & CEO: Hiroshi Hirata, “Gunze”), on January 27, 2012.

LIFE CHECK is a personal self-monitoring blood glucose meter with which diabetes patients can monitor their own blood glucose level by simply inserting a dedicated sensor known as the LIFE CHECK SENSOR into the meter. The meter was developed as a next-generation model of the blood glucose monitor G-CHECK currently manufactured by Gunze and marketed by EIDIA. While Gunze received approval to manufacture and market LIFE CHECK in August 2011, the system will be distributed and marketed by EIDIA and co-promoted by Eisai.

EIDIA

The LIFE CHECK meter employs a color liquid crystal screen that displays step-by-step operational instructions and easy-to-read graphs of measured data. After measurement, the dedicated sensor can be easily and safely removed from the meter with the push of a button without the patient having to touch the part to which their blood has been applied... Eisai's Press Release -

Thursday, August 7, 2008

Eisai China : License Agreement in China for alpha-Lipon 300 STADA for Diabetic Neuropathic Pain

July 30, 2008 - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced that Eisai China Inc. (Headquarters: Suzhou, President: Yukio Akada, “ECI”), a wholly-owned subsidiary of Eisai Co., Ltd., has entered into license agreement with Health Vision Enterprise Ltd. (Headquarters: Hong Kong, Directors: Alex Leung and Zona Yim, “Health Vision”), a sales subsidiary of STADA Arzneimittel AG (Headquarters: Germany, “STADA”), for sales and repack of alpha-Lipon 300 STADA® (generic name: alpha-lipoic acid) in China. alpha-Lipon 300 STADA® is a treatment for diabetic neuropathic pain developed by STADA.

With this agreement, ECI will take over sales promotion activities for alpha-Lipon 300 STADA® in China from Health Vision from August 1. In addition, ECI will prepare for filing an application for repacking the product at its Suzhou plant. Upon approval, ECI will assume repacking and sales of alpha-Lipon 300 STADA® in China.

alpha-Lipon 300 STADA® is a therapeutic agent for diabetic neuropathic pains developed by STADA, and has been on the market in China since 2005. It relieves neuropathic pain associated with diabetes by its antioxidant effect, which reduces overproduction of oxygen species and normalization of glucose metabolism... Eisai's Press Release -